Glenmark Pharmaceuticals Inc., USA, is set to launch Ropivacaine Hydrochloride Injection USP in various dosages: 40 mg/20 mL (2mg/mL), 150 mg/30 mL (5 mg/mL), and 200 mg/20 mL (10 mg/mL) single-dose vials. This product is bioequivalent and therapeutically equivalent to Naropin® Injection. Distribution is slated to begin in November 2025.
Ropivacaine Hydrochloride Injection Launch
Glenmark Pharmaceuticals Inc., USA (Glenmark) will soon launch Ropivacaine Hydrochloride Injection USP. The injection will be available in 40 mg/20 mL (2mg/mL), 150 mg/30 mL (5 mg/mL), and 200 mg/20 mL (10 mg/mL) single-dose vials.
Glenmark’s Ropivacaine Hydrochloride Injection USP versions are bioequivalent and therapeutically equivalent to Naropin® Injection, specifically the 40 mg/20 mL (2 mg/mL), 150 mg/30 mL (5 mg/mL), and 200 mg/20 mL (10 mg/mL) versions from Fresenius Kabi USA, LLC.
Distribution Timeline
Glenmark anticipates beginning distribution of this product in November 2025.
Market Overview
According to IQVIA® data for the 12 months ending August 2025, the market for Naropin® Injection (including 40 mg/20 mL, 150 mg/30mL, and 200 mg/20 mL versions) achieved annual sales of approximately $20.9 million*.
*IQVIA® National Sales Perspectives: Retail & Non-Retail, August 2025
Source: BSE
